Abstract
Eribulin mesylate (E) is indicated for metastatic breast cancer patients previously treated with anthracycline and taxane. We argued that E could also benefit patients eligible for neoadjuvant chemotherapy. Patients with primary triple negative breast cancer ≥2 cm received doxorubicin 60 mg/m2 and paclitaxel 200 mg/m2 x 4 cycles (AT) followed by E 1.4 mg/m2 x 4 cycles. Primary endpoint was pathological complete response (pCR) rate; secondary and explorative endpoints included clinical/metabolic response rates and safety, and biomarker analysis, respectively. Using a two-stage Simon design, 43 patients were to be included provided that 4 of 13 patients had achieved pCR in the first stage of the study. In stage I of the study 13 women were enrolled, median age 43 years, tumor size 2-5 cm in 9/13 (69%), positive nodal status in 8/13 (61%). Main grade 3 adverse event was neutropenia (related to AT and E in 4 and 2 cases, respectively). AT followed by E induced clinical complete + partial responses in 11/13 patients (85%), pCR in 3/13 (23%). Median measurements of maximum standardized uptake value (SUVmax) resulted 13, 3, and 1.9 at baseline, after AT and E, respectively. Complete metabolic response (CMR) occurred after AT and after...Continue Reading
References
Feb 16, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·H YoungP Price
Aug 18, 2004·Cancer Research·Galina KuznetsovBruce A Littlefield
Jul 16, 2005·Molecular Cancer Therapeutics·Mary Ann JordanLeslie Wilson
Dec 20, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Luca GianniUNKNOWN European Cooperative Trial in Operable Breast Cancer Study Group
Apr 18, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lisa A CareyCharles M Perou
Dec 8, 2007·Cancer Chemotherapy and Pharmacology·Rosalba TorrisiMarco Colleoni
Jul 23, 2008·Molecular Cancer Therapeutics·Tatiana OkounevaMary Ann Jordan
Apr 1, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Luca GianniGianni Bonadonna
Apr 8, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Linda T VahdatJoanne L Blum
Dec 17, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tomasz ByrskiSteven Narod
Jan 27, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel P SilverJudy E Garber
Jun 16, 2010·Cancer·Helena R ChangJeffrey Gornbein
Aug 4, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Javier CortesMary Ann Allison
Nov 12, 2010·The New England Journal of Medicine·William D FoulkesJorge S Reis-Filho
Mar 8, 2011·Lancet·Javier CortesUNKNOWN EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators
Dec 14, 2011·Lancet·R PetoK Pritchard
Nov 6, 2012·Breast Cancer Research and Treatment·L MalorniG Arpino
Feb 18, 2014·Lancet·Patricia CortazarGunter von Minckwitz
Feb 27, 2014·British Journal of Cancer·T YoshidaJ Matsui
Aug 30, 2014·PloS One·Zoltán DezsőYasuhiro Funahashi
Nov 9, 2014·Breast Cancer Research and Treatment·Chris TwelvesAhmad Awada
May 27, 2015·Breast Cancer Research and Treatment·Virginia G KaklamaniWilliam Gradishar
Jul 2, 2015·Breast Cancer Research and Treatment·Jame AbrahamSamuel A Jacobs
Feb 13, 2016·The Lancet Oncology·Michael UntchUNKNOWN Arbeitsgemeinschaft Gynäkologische Onkologie—Breast (AGO-B) Investigators
Apr 20, 2016·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·T SugiyamaH Oda
Jul 12, 2016·Breast Cancer : Basic and Clinical Research·Chris TwelvesPeter A Kaufman
Aug 9, 2017·Breast Care·Marzia A LocatelliAlexandru Eniu
Dec 16, 2017·The Lancet Oncology·UNKNOWN Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Jan 13, 2018·JAMA Oncology·Luca GianniIgnacio Tusquets
Mar 5, 2018·The Lancet Oncology·Sibylle LoiblCharles E Geyer
Jun 14, 2018·Clinical Breast Cancer·Karen A CadooTiffany A Traina